drugset / Trial / NCT02814643
Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma
RandomizedParallel-groupTriple-blindSupportive care
Summary
This is a randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of a fixed dose of benralizumab administered subcutaneously (SC) on antibody responses following seasonal influenza virus vaccination
Timeline
- Start
- 2016-07-01
- Primary completion
- 2017-01-24
- Completion
- 2017-01-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Benralizumab | Monoclonal antibody | — | Subcutaneous |
| Background | Seasonal influenza virus vaccine | Vaccine | — | Intramuscular |